GRM2 and schizophrenia: Nonetheless, mGluR2/3 activation was shown to reverse working memory deficits and BOLD (blood oxygenation level-dependent) signal induced by the NMDA receptor antagonist ketamine in healthy subjects [14, 15], supporting the NMDA receptor hypofunction hypothesis of schizophrenia [16–18].